C-suite level selling totaling over half a million dollars raises concerns about confidence in near-term valuation, especially following option exercises. Traders should watch for changes in forward guidance or upcoming clinical trial data that may have influenced timing. Monitor next 10-Q for potential revenue or pipeline updates.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $23.72entry
- T+1 · 7mo ago +0.89%α +0.63% · $23.93
- T+5 · 7mo ago −0.38%α −2.02% · $23.63
- T+20 · 6mo ago −5.65%α −11.69% · $22.38
- T+60 · 4mo ago +21.88%α +13.74% · $28.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bicara Therapeutics executives Claire Mazumdar (CEO) and Ryan Cohlhepp (President/COO) sold a combined $538,203 worth of shares in open-market transactions over a 6-day window. These sales follow derivative exercises and represent material insider selling by two top executives.
Key Financial Metrics
Key Facts
- CEO Claire Mazumdar sold 15,000 shares for $354,145.50 on April 20, 2026, following multiple derivative exercises.
- President and COO Ryan Cohlhepp sold 8,000 shares for $184,058.40 on April 15, 2026, after exercising derivatives.
- Total open-market sales in the cluster amount to $538,203, representing approximately 0.034% of the company's $1.6B market cap.
- Both executives exercised in-the-money options prior to selling, with some transactions involving non-cash exercises (code M).
Financial Impact
$538,203 in open-market sales by C-suite executives
Risk Factors
- Perception of insider pessimism despite non-cash exercises being routine
- Potential for negative market reaction due to concentrated selling by top leadership
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BCAX-1776727656831 |
Track record
26 reports on BCAX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers